ENGNW - enGene Holdings Inc. Warrants
Price:
--
--
About enGene Holdings Inc. Warrants (https://www.engene.com)
EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer & Director | 1963 | $1,213,529 USD |
| David Ryan Daws | Chief Financial Officer & Head of Business Development | 1974 | $719,029 USD |
| Lee G. Giguere | Chief Legal Officer & Corporate Secretary | 1980 | $605,448 USD |
| Alex Nichols | Chief Strategy & Operations Officer | 1986 | $504,442 USD |
| Anthony T. Cheung | Co-Founder & Chief Scientific Officer | 1972 | $341,754 USD |
| Hussein Sweiti | Chief Medical Officer and Head of Research & Development | 1987 | $257,562 USD |
| Amy Pott | Chief Global Commercialization Officer | 1976 | – |
| Jill Buck | Chief Development Officer | 1974 | – |
| Joan Connolly | Chief Technology Officer | 1970 | – |
| Matthew Boyd | Chief Regulatory Officer | 1974 | – |
| Tara Place | Senior Vice President of Human Resources | – | – |